Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

Summary

This is a single center, single arm phase 2 study to establish the safety and efficacy of itacitinib (also known as INCB039110) administered in combination with pembrolizumab in patients with metastatic PD-L1 positive non-small cell lung cancer (NSCLC).

Timeline

Start

2018-06-18

Primary completion

2021-06-17

Completion

2021-10-11

Drugs

Indications